Literature DB >> 11961119

Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons.

Alessandra Mallei1, Bitao Shi, Italo Mocchetti.   

Abstract

New experimental evidence suggests that the mechanism of action of antidepressants includes the induction of neurotrophic factor synthesis in selected brain areas. The present study is aimed at establishing whether prolonged antidepressant treatments increase the expression of basic fibroblast growth factor (FGF2), a polypeptide growth factor that has a broad neurotrophic activity in the adult central nervous system. Rats received a single dose or long-term (3 weeks) administration of desipramine (DMI), fluoxetine (FLU), and mianserin (MIA), then were sacrificed at 5 and 24 h after the last injection. RNase protection assay and Western blot analysis revealed that all antidepressant drugs elicited an anatomically specific increase in FGF2 mRNA and protein. The increase in FGF2 mRNA after a single injection was seen only at 5 h after the injection and was restricted to the entorhinal cortex, whereas the effect of the long-term treatments lasted up to 24 h and occurred in the entire cortex and hippocampus. Immunohistochemical analysis of FGF2 immunoreactivity was carried out to investigate which cell types responded to the antidepressant treatments. DMI and MIA increased FGF2 proteins predominantly in neurons of layer V throughout the cerebral cortex and in some neurofilament-positive cells of the hippocampus. FLU increased FGF2 immunoreactivity mainly in neurofilament-positive cells of the hippocampus. These findings may explain the therapeutic efficacy of antidepressants in affective disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11961119     DOI: 10.1124/mol.61.5.1017

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  43 in total

1.  Fibroblast growth factor-2 (FGF2) augmentation early in life alters hippocampal development and rescues the anxiety phenotype in vulnerable animals.

Authors:  Cortney A Turner; Sarah M Clinton; Robert C Thompson; Stanley J Watson; Huda Akil
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

Review 2.  Implementing neuronal plasticity in NeuroAIDS: the experience of brain-derived neurotrophic factor and other neurotrophic factors.

Authors:  Italo Mocchetti; Alessia Bachis; Lee A Campbell; Valeriya Avdoshina
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-06       Impact factor: 4.147

Review 3.  Moonlighting proteins and protein-protein interactions as neurotherapeutic targets in the G protein-coupled receptor field.

Authors:  Kjell Fuxe; Dasiel O Borroto-Escuela; Wilber Romero-Fernandez; Miklós Palkovits; Alexander O Tarakanov; Francisco Ciruela; Luigi F Agnati
Journal:  Neuropsychopharmacology       Date:  2013-09-06       Impact factor: 7.853

Review 4.  Functional biomarkers of depression: diagnosis, treatment, and pathophysiology.

Authors:  Heath D Schmidt; Richard C Shelton; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

Review 5.  Gap junction channels as potential targets for the treatment of major depressive disorder.

Authors:  Qian Ren; Zhen-Zhen Wang; Shi-Feng Chu; Cong-Yuan Xia; Nai-Hong Chen
Journal:  Psychopharmacology (Berl)       Date:  2017-11-25       Impact factor: 4.530

6.  Fibroblast growth factor-2: an endogenous antidepressant and anxiolytic molecule?

Authors:  Cortney A Turner; Stanley J Watson; Huda Akil
Journal:  Biol Psychiatry       Date:  2012-08-15       Impact factor: 13.382

7.  Interaction of FGF-2 with IGF-1 and BDNF in stimulating Akt, ERK, and neuronal survival in hippocampal cultures.

Authors:  Nadine N Johnson-Farley; Khushboo Patel; Deborah Kim; Daniel S Cowen
Journal:  Brain Res       Date:  2007-04-19       Impact factor: 3.252

8.  Antidepressant-like effects of intracerebroventricular FGF2 in rats.

Authors:  Cortney A Turner; Edny L Gula; Larry P Taylor; Stanley J Watson; Huda Akil
Journal:  Brain Res       Date:  2008-06-14       Impact factor: 3.252

Review 9.  Role of neurotrophic factors in the etiology and treatment of mood disorders.

Authors:  Ronald S Duman
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

Review 10.  The fibroblast growth factor family: neuromodulation of affective behavior.

Authors:  Cortney A Turner; Stanley J Watson; Huda Akil
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.